PARIS, June 18, 2025 (GLOBE NEWSWIRE) — Gradient Denervation Technologies announced today that it has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot from the U.S. Food and Drug Administration (FDA) for the development of its novel technology intended to treat patients with pulmonary hypertension and associated heart failure. The TAP Pilot acceptance follows the Company’s recent announcement that the FDA granted Breakthrough Device Designation for the Gradient Denervation System.

Company plans Early Feasibility Study in the US for late 2023 PARIS, FRANCE / ACCESSWIRE / June 1, 2023 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive device for treating certain heart failure patients with associated pulmonary hypertension, announced today the successful first patient enrollment in its […]